Inhibition of reovirus by Mycophenolic acid is associated with the M1 genome segment

Journal of Virology

Volumn 78, Issue 12, 2004, Pages 6171-6179

  Hermann, Laura L ^a   Coombs, Kevin M ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; GUANOSINE; GUANOSINE TRIPHOSPHATE; INOSINATE DEHYDROGENASE INHIBITOR; MU 1 PROTEIN; MU 2 PROTEIN; MYCOPHENOLIC ACID; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; GENETIC REASSORTMENT; HUMAN; HUMAN CELL; M1 GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; REOVIRUS; RNA SYNTHESIS; STRAIN DIFFERENCE; VIRUS GENE; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSCRIPTION;

ANIMALS; CERCOPITHECUS AETHIOPS; ENZYME INHIBITORS; GENOME, VIRAL; HUMANS; L CELLS (CELL LINE); MICE; MYCOPHENOLIC ACID; ORTHOREOVIRUS; RNA, VIRAL; VERO CELLS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 2642518684     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.12.6171-6179.2004     Document Type: Article

References (72)

1. Allison, A. C., and E. M. Eugui. 2000. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47:85-118.
2. Behrend, M., R. Lueck, and R. Pichlmayr. 1997. Long-term experience with mycofenolate mofetil in the prevention of renal allograft rejection. Transplant. Proc. 29:2927-2929.
3. Berman, J. D., and H. K. Webster. 1982. In vitro effects of mycophenolic acid and allopurinol against Leishmania tropica in human macrophages. Antimicrob. Agents Chemother. 21:887-891.
4. Brentano, L., D. L. Noah, E. G. Brown, and B. Sherry. 1998. The reovirus protein μ2, encoded by the M1 gene, is an RNA-binding protein. J. Virol. 72:8354-8357.
5. Brown, E. G., M. L. Nibert, and B. N. Fields. 1983. The L2 gene of reovirus serotype 3 controls the capacity to interfere, accumulate deletions, and establish persistent infection, p. 275-287. In R. W. Compans and D. H. L. Bishop (ed.), Double-stranded RNA viruses. Elsevier Biomedical, New York, N.Y.
6. Butler, M., A. Burgener, M. Patrick, M. Berry, D. Moffatt, N. Huzel, N. Barnabe, and K. Coombs. 2000. Application of a serum-free medium for the growth of Vero cells and the production of reovirus. Biotechnol. Prog. 16:854-858.
7. Carter, S. B., T. J. Franklin, D. F. Jones, B. J. Leonard, S. D. Mills, R. W. Turner, and W. B. Turner. 1969. Mycophenolic acid: an anti-cancer compound with unusual properties. Nature 223:848-850.
8. Cleveland, D. R., H. Zarbl, and S. Millward. 1986. Reovirus guanylyltransferase is L2 gene product lambda 2. J. Virol. 60:307-311.
9. Connolly, J. L., and T. S. Dermody. 2002. Virion disassembly is required for apoptosis induced by reovirus. J. Virol. 76:1632-1641.
10. Coombs, K. M. 1998. Stoichiometry of reovirus structural proteins in virus, ISVP, and core particles. Virology 243:218-228.
11. Coombs, K. M., B. N. Fields, and S. C. Harrison. 1990. Crystallization of the reovirus type 3 Dearing core. Crystal packing is determined by the lambda 2 protein. J. Mol. Biol. 215:1-5.
12. Coombs, K. M., S. C. Mak and L. D. Petrycky-Cox. 1994. Studies of the major reovirus core protein sigma 2: reversion of the assembly-defective mutant tsC447 is an intragenic process and involves back mutation of Asp-383 to Asn. J. Virol. 68:177-186.
13. Dargan, D. J., C. B. Gait, and J. H. Subak-Sharpe. 1992. The effect of cicloxolone sodium on the replication in cultured cells of adenovirus type 5, reovirus type 3, poliovirus type 1, two bunyaviruses and Semliki Forest virus. J. Gen. Virol. 73:407-411.
14. De Clercq, E. 1993. Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. Adv. Virus Res. 42:1-55.
15. De Clercq, E. 2001. 2001 ASPET Otto Krayer Award Lecture. Molecular targets for antiviral agents. J. Pharmacol. Exp. Ther. 297:1-10.
16. De Clercq, E. 2001. Antiviral drugs: current state of the art. J. Clin. Virol. 22:73-89.
17. De Clercq, E., R. Bernaerts, Y. F. Shealy, and J. A. Montgomery. 1990. Broad-spectrum antiviral activity of carbodine, the carbocyclic analogue of cytidine. Biochem. Pharmacol. 39:319-325.
18. De Clercq, E., M. Cools, J. Balzarini, V. E. Marquez, D. R. Borcherding, R. T. Borchardt, J. C. Drach, S. Kitaoka, and T. Konno. 1989. Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5′-nor derivatives, Antimicrob. Agents Chemother. 33:1291-1297.
19. De Clercq, E., L. Naesens, L. De Bolle, D. Schols, Y. Zhang, and J. Neyts. 2001. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev. Med. Virol. 11:381-395.
20. Diamond, M. S., M. Zachariah, and E. Harris. 2002. Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology 304:211-221.
21. Drayna, D., and B. N. Fields. 1982, Genetic studies on the mechanism of chemical and physical inactivation of reovirus. J. Gen. Virol. 63:149-159.
22. Dryden, K. A., D. L. Farsetta, G. Wang, J. M. Keegan, B. N. Fields, T. S. Baker, and M. L. Nibert. 1998. Internal structures containing transcriptase-related proteins in top component particles of mammalian orthoreovirus. Virology 245:33-46.
23. Estes, M. K. 2001. Rotaviruses and their replication, p. 1747-1786. In D. M. Knipe and P. M. Howley (ed)., Fields virology. Lippincott Williams & Wilkins, Philadelphia, Pa.
24. Gong, Z. J., S. De Meyer, C. Clarysse, C. Verslype, J. Neyts, E. De Clercq, and S. H. Yap. 1999. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J. Viral Hepat. 6:229-236.
25. Haller, B. L., M. L. Barkon, G. P. Vogler, and H. W. Virgin IV. 1995. Genetic mapping of reovirus virulence and organ tropism in severe combined immunodeficient mice: organ-specific virulence genes. J. Virol. 69:357-364.
26. Hazelton, P. R., and K. M. Coombs. 1995. The reovirus mutant tsA279 has temperature-sensitive lesions in the M2 and L2 genes: the M2 gene is associated with decreased viral protein production and blockade in transmembrane transport. Virology 207:46-58.
27. Heredia, A., D. Margolis, D. Oldach, R. Hazen, N. Le, and R. Redfield. 1999. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. J. Acquir. Immune Defic. Syndr, 22:406-407.
28. Hossain, M. M., J. J. Coull, G. L. Drusano, and D. M. Margolis. 2002. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antivir. Res. 55:41-52.
29. Hupe, D. J., B. A. Azzolina, and N. D. Behrens. 1986. IMP dehydrogenase from the intracellular parasitic protozoan Eimeria tenella and its inhibition by mycophenolic acid. J. Biol. Chem. 261:8363-8369.
30. Ichimura, H., and J. A. Levy. 1995. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 211:554-560.
31. Keast, D., and A. R. Vasquez. 1992. Inhibition in vitro of the replication of murine cytomegalovirus or reovirus type 3 by the glutamine analogue acivicin. Arch. Virol. 124:235-244.
32. Keirstead, N. D., and K. M. Coombs. 1998. Absence of superinfection exclusion during asynchronous reovirus infections of mouse, monkey, and human cell lines. Virus Res. 54:225-235.
33. Kobashigawa, J., L. Miller, D. Renlund, R. Mentzer, E. Alderman, R. Bourge, M. Costanzo, H. Eisen, G. Dureau, R. Ratkovec, M. Hummel, D. Ipe, J. Johnson, A. Keogh, R. Mamelok, D. Mancini, F. Smart, H. Valantine, et al. 1998. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 66:507-515.
34. Labrada, L., G. Bodelon, J. Vinuela, and J. Benavente. 2002. Avian reoviruses cause apoptosis in cultured cells: viral uncoating, but not viral gene expression, is required for apoptosis induction. J. Virol. 76:7932-7941.
35. Lehninger, A. L., D. L. Nelson, and M. M. Cox. 1993. Principles of biochemistry, p. 688-735. Worth Publishers, New York, N.Y.
36. Luongo, C. L., C. M. Contreras, D. L. Farsetta, and M. L. Nibert. 1998. Binding site for S-adenosyl-L-methionine in a central region of mammalian reovirus lambda2 protein. Evidence for activities in mRNA cap methylation. J. Biol. Chem. 273:23773-23780.
37. Malinoski, F., and V. Stollar. 1981. Inhibitors of IMP dehydrogenase prevent Sindbis virus replication and reduce GTP levels in Aedes albopictus cells. Virology 110:281-289.
38. Margolis, D., A. Heredia, J. Gaywee, D. Oldach, G. Drusano, and R. Redfield. 1999. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J. Acquir. Immune Defic. Syndr. 21:362-370.
39. Matoba, Y., B. Sherry, B. N. Fields, and T. W. Smith. 1991. Identification of the viral genes responsible for growth of strains of reovirus in cultured mouse heart cells. J. Clin. Investig. 87:1628-1633.
40. Mbisa, J. L., M. M. Becker, S. Zou, T. S. Dermody, and E. G. Brown. 2000. Reovirus mu2 protein determines strain-specific differences in the rate of viral inclusion formation in L929 cells. Virology 272:16-26.
41. McCrae, M. A., and W. K. Joklik. 1978. The nature of the polypeptide encoded by each of the 10 double-stranded RNA segments of reovirus type 3. Virology 89:578-593.
42. Mitsui, A., and S. Suzuki. 1969. Immunosuppressive effect of mycophenolic acid. J. Antibiot. (Tokyo) 22:358-363.
43. Mizuno, K., M. Tsujino, M. Takada, M. Hayashi, and K. Atsumi. 1974. Studies on bredinin. I. Isolation, characterization and biological properties. J. Antibiot. (Tokyo) 27:775-782.
44. Moody, M. D., and W. K. Joklik. 1989. The function of reovirus proteins during the reovirus multiplication cycle: analysis using monoreassortants. Virology 173:437-446.
45. Morrey, J. D., D. F. Smee, R. W. Sidwell, and C. Tseng. 2002. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antivir. Res. 55:107-116.
46. Mustoe, T. A., R. F. Ramig, A. H. Sharpe, and B. N. Fields. 1978. Genetics of reovirus: identification of the dsRNA segments encoding the polypeptides of the mu and sigma size classes. Virology 89:594-604.
47. Neyts, J., G. Andrei, and E. De Clercq. 1998. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob. Agents Chemother. 42:216-222.
48. Neyts, J., and E. De Clercq. 1998. Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir. Antivir. Res. 40:53-56.
49. Nibert, M. L., R. L. Margraf, and K. M. Coombs. 1996. Nonrandom segregation of parental alleles in reovirus reassortants. J. Virol. 70:7295-7300.
50. Nibert, M. L., and L. A. Schiff. 2001. Reoviruses and their replication, p. 1679-1728. In D. M. Knipe and P. M. Howley (ed.), Fields virology. Lippincott Williams & Wilkins, Philadelphia, Pa.
51. Noble, S., and M. L. Nibert. 1997. Core protein μ2 is a second determinant of nucleoside triphosphatase activities by reovirus cores. J. Virol. 71:7728-7735.
52. Obara, T., S. Shuto, Y. Saito, R. Snoeck G. Andrei, J. Balzarini, E. De Clercq, and A. Matsuda. 1996. New neplanocin analogues. 7. Synthesis and antiviral activity of 2-halo derivatives of neplanocin A. J. Med. Chem. 39:3847-3852.
53. Parker, J. S., T. J. Broering, J. Kim, D. E. Higgins, and M. L. Nibert. 2002. Reovirus core protein μ2 determines the filamentous morphology of viral inclusion bodies by interacting with and stabilizing microtubules. J. Virol. 76:4483-4496.
54. Qiu, T., and C. L. Luongo. 2003. Identification of two histidines necessary for reovirus mRNA guanylyltransferase activity. Virology 316:313-324.
55. Rankin, J. T., Jr., S. B. Eppes, J. B. Antczak, and W. K. Joklik. 1989. Studies on the mechanism of the antiviral activity of ribavirin against reovirus. Virology 168:147-158.
56. Reinisch, K. M., M. L. Nibert, and S. C. Harrison. 2000. Structure of the reovirus core at 3.6 A resolution. Nature 404:960-967.
57. Richman, D. D., R. S. Kornbluth, and D. A. Carson. 1987. Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages. J. Exp. Med. 166:1144-1149.
58. Robins, M. J., S, F. Wnuk, X. Yang, C. S. Yuan, R. T. Borchardt, J. Balzarini, and E. De Clercq. 1998. Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5′,5′,6′,6′ -tetradehydro-6′-deoxy-6′-halo-homoadenosine analogues (4′-haloacetylene analogues derived from adenosine). J. Med. Chem. 41:3857-3864.
59. Roy, P. 2001. Orbiviruses, p. 1835-1870. In D. M. Knipe and P. M. Howley (ed.), Fields virology. Lippincott Williams & Wilkins, Philadelphia, Pa.
60. Scheidel, L. M., and V. Stollar. 1991. Mutations that confer resistance to mycophenolic acid and ribavirin on Sindbis virus map to the nonstructural protein nsP1. Virology 181:490-499.
61. Sherry, B., and B. N. Fields. 1989. The reovirus M1 gene, encoding a viral core protein, is associated with the myocarditic phenotype of a reovirus variant. J. Virol. 63:4850-4856.
62. Sherry, B., J. Torres, and M. A. Blum. 1998. Reovirus induction of and sensitivity to beta interferon in cardiac myocyte cultures correlate with induction of myocarditis and are determined by viral core proteins. J. Virol. 72:1314-1323.
63. Sidwell, R. W., J. H. Huffman, G. P. Khare, L. B. Allen, J. T. Witkowski, and R. K. Robins. 1972. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705-706.
64. Sintchak, M. D., and E. Nimmesgern. 2000. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 47:163-184.
65. Smee, D. F., M. Bray, and J. W. Huggins. 2001. Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. Antivir. Chem. Chemother. 12:327-335.
66. Sollinger, H. W., et al. 1995. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60:225-232.
67. Swanson, M. I., Y. M. She, W. Ens, E. G. Brown, and K. M. Coombs. 2002. Mammalian reovirus core protein micro 2 initiates at the first start codon and is acetylated. Rapid Commun. Mass Spectrom. 16:2317-2324.
68. Tyler, K. L. 2001. Mammalian reoviruses, p. 1729-1745. In D. M. Knipe and P. M. Howley (ed.) Fields virology. Lippincott Williams & Wilkins, Philadelphia, Pa.
69. Wiener, J. R., J. A. Bartlett, and W. K. Joklik. 1989. The sequences of reovirus serotype 3 genome segments M1 and M3 encoding the minor protein mu 2 and the major nonstructural protein mu NS, respectively. Virology 169:293-304.
70. Williams, R. H., D. H. Lively, D. C. DeLong, J. C. Cline, and M. J. Sweeny. 1968. Mycophenolic acid: antiviral and antitumor properties. J. Antibiot. (Tokyo) 21:463-464.
71. Yin, P., M. Cheang, and K. M. Coombs. 1996. The M1 gene is associated with differences in the temperature optimum of the transcriptase activity in reovirus core particles. J. Virol. 70:1223-1227.
72. Zou, S., and E. G. Brown. 1992. Nucleotide sequence comparison of the M1 genome segment of reovirus type 1 Lang and type 3 Dearing. Virus Res. 22:159-164.